Objectives. To compare the prevalence of and predictors for sustained drug-free remission in two cohorts of patients with recent-onset RA treated with DAS-driven therapy or non-DAS-driven therapy.
Introduction
In RA, an early start of treatment, use of combination therapy with CSs or TNF blockers, and a strategy of tight control have significantly improved the clinical and radiographic outcomes of patients [16] . Continued tight control aimed at a predefined goal of minimal disease activity has resulted in suppressed inflammation, improved functional status and high remission percentages, irrespective of the initial choice of therapy [7, 8] . Recently an international task force has reviewed and summarized all the evidence on tight control of RA and has formulated recommendations to enhance the implementation of treating to target in clinical practice [9, 10] .
According to these recommendations, the primary target of RA treatment should be a state of clinical remission, defined as the absence of signs and symptoms of inflammatory disease activity, assessed by a validated (composite) measure such as DAS [10, 11] . Ideally, clinical remission is maintained even after discontinuation of treatment, resulting in what could be called cure. In the Behandel Strategieen (BeSt) study, which combined an early start of treatment with DAS-driven therapy adjustments, the attainment of clinical remission (DAS-44<1.6) from Year 3 onwards led to tapering and ultimately discontinuation of DMARDs according to the pre-specified treatment protocol. After 5 years, 1019% of the patients in the four strategy groups were in drug-free remission with a median duration of 23 months [7] . Does DAS-driven therapy result in more drug-free remission than routine non-DAS-driven treatment? It is known that a proportion of patients treated according to routine care have been able to discontinue their anti-rheumatic medication [1214] . DAS-driven therapy might have a benefit by increasing the proportion of patients who achieve and maintain sustained drug-free remission, by inducing remission earlier in the disease course, in patients with more severe disease or all of these alternatives.
To investigate this, we set out to retrospectively compare the prevalence and predictors of sustained drug-free remission in two cohorts of recent-onset RA patients originating from the same region and treated with either DAS-driven or non-DAS-driven therapy. Because ACPAs are known to be an important predictive factor for disease outcome in RA, and current pathophysiological concepts consider ACPA-positive and ACPA-negative RA as two distinct disease entities [14, 15] , all outcomes were investigated separately in ACPA-positive and ACPA-negative patients.
Materials and methods

Patients
Two cohorts of patients were compared:
(i) The BeSt study (DAS-driven therapy cohort): 508 patients with recent-onset RA according to the 1987 ACR criteria [16] , a symptom duration <2 years and active disease at baseline [5 6 /66 swollen joints, 5 6/68 tender joints and either an ESR 5 28 mm/h or a global health score 5 20 mm on a visual analogue scale (VAS) of 0100 mm], who were randomized to four different DAS-driven treatment strategies. The inclusion period was 200002 [17] . (ii) The Leiden Early Arthritis Clinic (EAC) (non-DASdriven therapy cohort): 424 patients with recent-onset RA according to the 1987 ACR criteria from an observational inception cohort of consecutive arthritis patients with a symptom duration <2 years. The inclusion period was 19932002 [18] . In contrast to a previous report on the EAC [14] , 30 patients who also participated in the BeSt study were excluded.
The protocols of both cohorts were approved by the local ethics committees and the Leiden University Medical Center (LUMC) medical ethics committee, and all participants provided written informed consent.
Treatment
In the BeSt study, patients were randomized to one of four treatment groups: initial MTX monotherapy subsequently replaced by or extended with other DMARDs (Groups 1 and 2), initial combination therapy including conventional DMARDs and prednisone (Group 3) or initial combination therapy including infliximab (Group 4). Every 3 months the DAS-44 was calculated and treatment was adjusted following a strict protocol, aiming at a DAS-4442. 4 . If the DAS-44 was 42.4 for at least 6 consecutive months, medication was tapered to monotherapy in maintenance dose. Subsequently, from the third year of the study, if the DAS-44 was <1.6 for at least an additional 6 consecutive months, the last DMARD was tapered and discontinued. If the DAS-44 increased to >1.6, the last DMARD was immediately restarted. Details of the treatment protocol can be found elsewhere [17, 19] .
Patients in the EAC were treated according to the clinical judgement of their rheumatologist via non-DAS-based efficacy evaluations [18] . The treatment strategy differed according to the inclusion period. Patients included from 1993 to 1996 were initially treated with analgesics and subsequently with chloroquine. Between 1996 and 1998, patients were initially treated with chloroquine or SSZ, while after 1998 the initial treatment strategy consisted of either SSZ or MTX [14] . The initial treatment of the patients described in the current manuscript consisted of NSAIDs in 27% or DMARDs (with or without NSAIDs) in 73% of patients. Of all patients, 37% started with DMARD-combination therapy, and 15% initially used (also) CSs. Tapering and discontinuation of the medication was not protocolized.
Definition of remission
In the DAS-driven cohort, sustained drug-free remission was defined as a continued DAS-44<1.6 after discontinuation of DMARDs. In 85% of the patients in drug-free remission the swollen joint count (SJC) was zero, as based on systematically performed 66/68 joint counts at the 3-monthly follow-up visits. In the non-DAS-driven cohort patients, the DAS was not routinely performed, nor was it calculated post hoc or imputed. A full joint count was registered yearly. In the non-DAS-driven cohort, drug-free remission was defined according to the rheumatologist and required the absence of swollen joints after cessation of therapy.
In both cohorts, drug-free remission had to be present for at least 1 year, and had to persist until the end of follow-up, which for the patients in the DAS-driven cohort was the 5-year follow-up time point. In the www.rheumatology.oxfordjournals.org non-DAS-driven cohort, patients thus defined as being in drug-free remission were discharged from the outpatient clinic after an average of 2.5 years of drug-free remission. After that there was no systematic follow-up, but if patients had a recurrence of their arthritis after discharge, they were instructed to return to the Leiden University Medical Center. During the period under investigation, one patient was re-referred with a relapse and was therefore included in the non-remission group.
Seventy-two patients (14%) in the DAS-driven cohort dropped out or were lost to follow-up, and 31 patients (7.3%) in the non-DAS-driven cohort were lost to follow-up before the 5-year end-point due to withdrawal, death or moving. An intention-to-treat analysis with last observation carried forward approach was used.
Statistical analysis
The prevalence of sustained drug-free remission was assessed in both treatment cohorts (DAS-driven and non-DAS-driven). Since ACPA has been previously reported as a predictive factor for drug-free remission, cross-tabs stratified for ACPA were made and odds ratios (ORs) with 95% CIs for DAS-driven vs non-DASdriven therapy were calculated.
Baseline variables were assessed for their ability to predict the outcome of sustained drug-free remission by univariable logistic regression analysis in both cohorts separately. Predictors, which had previously been reported and with a P<0.10 in univariable analysis, were taken along in a multivariable analysis with a backward selection procedure (removal criterion: P >0.10), yielding independent predictors for sustained drug-free remission in both cohorts separately.
Next, we investigated whether DAS-driven treatment was a predictor for sustained drug-free remission by performing a multivariable logistic regression analysis on a combined data set of both cohorts. The treatment strategy (DAS-driven vs non-DAS-driven) was indicated by a variable (therapy) in this combined data set. To take into account that baseline patient characteristics differed between the two cohorts, baseline dissimilarities were corrected for by propensity scores, constructed from the variables age, gender, symptom duration, swollen joint count, ESR, RF and ACPA and all significant two-way interactions [20] . Via interaction terms we analysed whether the effect of DAS-driven therapy on drug-free remission was different for ACPA-positive or ACPA-negative patients.
Subsequently, sensitivity analyses were performed to assess whether the early use of combination therapy in the DAS-driven cohort or the earlier inclusion period (associated with treatment choice) in the non-DASdriven cohort had influenced the analyses. The sensitivity analysis was performed on the patients who received initial DMARD monotherapy, the patients being from Arms 1 and 2 in the DAS-driven cohort, and patients included after 1998 in the non-DAS-driven cohort.
Results
Cohort characteristics and prevalence of sustained drug-free remission At baseline, due to inclusion criteria of the BeSt study, patients in the DAS-driven therapy cohort had a longer symptom duration, more active disease characterized by worse function measured by the HAQ and a higher SJC, and were more often RF-or ACPA-positive than patients in the non-DAS-driven cohort (Table 1) . After 5 years of follow-up, the prevalence of sustained drug-free remission was 50/508 = 9.8% in the DAS-driven therapy cohort and 45/424 = 10.6% in the non-DAS-driven cohort ( Table 2 ). All four treatment arms of the DAS-driven study were included in the present analysis and there were no significant differences between the treatment arms. Stratified for ACPA, the prevalence of sustained drug-free remission was 20% in ACPA-negative RA patients, irrespective of the therapy cohort. The prevalence of drug-free remission was markedly lower in ACPA-positive patients (25%). ACPA-positive patients treated with DAS-driven therapy had a higher chance of achieving drug-free remission compared with non-DAS-driven therapy (OR 2.68, 95% CI 0.97, 7.43, P=0.058).
In the DAS-driven cohort, the discontinuation of anti-rheumatic therapy was prohibited by treatment protocol before 2.5 years of follow-up. The mean time (with S.D.) to drug-free remission was 3.1 (0.5) years in the DAS-driven cohort and 2.6 (1.3) years in the non-DAS-driven therapy cohort.
Predictive factors
In the DAS-driven cohort, male gender, lower DAS and HAQ at baseline and the absence of RF, ACPA and shared epitope (SE) alleles were significantly univariately associated with sustained drug-free remission ( Table 3) . The allocated initial treatment or treatment arm (mono-vs combination therapy) was not a predictive factor (data not shown). The multivariate model revealed male gender, short symptom duration, the absence of ACPA and lower baseline DAS as independent predictors for sustained drug-free remission in the DAS-driven cohort (Table 4) . If the DAS was replaced with the HAQ, the HAQ was also an independent predictor with borderline significance (OR 0.61, 95% CI 0.37, 1.006, P = 0.053). RF was a significant independent predictor if put in the model instead of ACPA (OR 0.33, 95% CI 0.18, 0.60, P 40.001), but was not significant if included in addition to ACPA.
Also in the non-DAS-driven cohort, the absence of RF, ACPA and SE were significant univariate predictors (Table 3 ). In addition, shorter symptom duration and non-smoking were identified as predictors. The inclusion period as surrogate variable for the initial treatment was not predictive for sustained drug-free remission (data not shown). The multivariable model revealed a shorter symptom duration and the absence of ACPA as independent predictors for sustained drug-free remission in the non-DAS-driven cohort (Table 4) . Again, RF was only a significant independent predictor if put in the model instead of ACPA (OR 0.25, 95% CI 0.12, 0.51, P 40.001).
Looking at the effect of ACPA positivity, the OR for sustained drug-free remission was two times higher with DAS-driven therapy (OR 0.20) than with non-DAS-driven therapy (OR 0.09), suggesting that the negative effect of having ACPA on achieving sustained drug-free remission may be counterbalanced to some extent by a benefit of DAS-driven therapy.
The multivariable logistic regression analysis with the two data sets combined included age, gender, symptom duration, smoking, ESR, CRP, RF, ACPA and treatment cohort as explanatory variables and was corrected for propensity scores to take into account the differences in baseline characteristics between the two cohorts. The model revealed male gender, short symptom duration and the absence of ACPA as independent predictors for sustained drug-free remission (Table 5) . DAS-driven therapy was not associated with a significantly higher chance for sustained drug-free remission in this multivariable model. However, a significant interaction was present between treatment cohort and ACPA (OR 3.2, 95% CI 1.04, 10.1, P=0.043). We therefore investigated the effect of treatment cohort separately for ACPA-positive and ACPA-negative patients. As shown in Table 5 , DAS-driven therapy was associated with a three times greater chance for sustained drug-free remission in ACPA-positive patients, but not in ACPA-negative patients, confirming our univariable findings. Prevalence of sustained drug-free remission in the DAS-driven and the non-DAS-driven therapy cohort, in the total group and stratified for ACPA-positive and ACPA-negative patients. ORs with 95% CIs represent the chance for drug-free remission with DAS-driven vs non-DAS-driven therapy.
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TABLE 3
Characteristics of patients who did or did not achieve sustained drug-free remission 25 (3) 26 (4) 0.96 (0.88, 1.04)
25 (3) 26 ( 34 (1754) 37 (2260) 1.00 (0.99, 1.01) RF positive, n (%)
22 (44) 307 ( Characteristics of patients who did or did not achieve sustained drug-free remission after 5 years in the DAS-driven therapy cohort (BeSt) and non-DAS-driven therapy cohort (EAC).
ORs with 95% CIs are presented from the univariable logistic regression analyses. *Statistically significant. NA: not available, SHS: Sharpvan der Heijde score.
Sensitivity analysis
The analyses in the total cohorts did not reveal treatment allocation in the DAS-driven cohort nor the inclusion period in the non-DAS-driven cohort as factors associated with achieving drug-free remission. Nevertheless, to investigate if the differences in initial treatment and the inclusion period within and between the cohorts influenced our results, we performed a sensitivity analysis on the patients who received comparable initial DMARD monotherapy in a similar time period. The prevalence of sustained drug-free remission was 25/247 (10.1%) in the patients treated with initial MTX monotherapy in the DAS-driven cohort and 19/199 (9.5%) in the patients included after 1998 in the non-DAS-driven cohort, treated with either initial MTX or SSZ monotherapy. In the DAS-driven cohort, independent multivariate predictors for drug-free remission remained male gender (OR 2.1, 95% CI 0.84, 5.35, P = 0.112), absence of ACPA (OR 0.23, 95% CI 0.09, 0.59, P = 0.002) and short symptom duration (OR 0.98, 95% CI 0.96, 0.99, P = 0.038). In the non-DAS-driven cohort, only absence of ACPA remained a significant independent predictor (OR 0.09, 95% CI 0.02, 0.41, P = 0.002).
Discussion
Although it is clear that tight-control strategies such as DAS-driven therapy result in better clinical and radiographic outcomes, and recommendations for treating RA to target have recently been formulated, it has not yet been investigated whether DAS-driven therapy also results in more drug-free remission than non-DAS-driven routine treatment evaluations [9, 10] . In this study we found that in two cohorts of patients with recent-onset RA treated with either DAS-driven or non-DAS-driven therapy, the occurrence of sustained drug-free remission was fairly similar, as were predictors of sustained drug-free remission: a short symptom duration and the absence of ACPA.
Since there were significant differences between the two cohorts at baseline, the comparison is not straightforward. A randomized controlled trial would be the ideal setting to investigate the effect of DAS-driven vs non-DAS-driven therapy on achieving sustained drug-free remission. However, as DAS-driven therapy leads to better functional and radiological outcomes than non-DAS-driven therapy [2, 6, 19] such a design may be considered unethical. In addition, large patient numbers per group would be required, since sustained drug-free remission does not occur often. Therefore we resorted to a retrospective comparison of two existing large cohorts.
Patients in the DAS-driven cohort, which started as the BeSt trial, had more severe disease and therefore poorer prognosis, based on the inclusion criteria of the trial [17] , whereas the non-DAS-driven cohort also included less severe patients [18] . In addition, the definition of sustained drug-free remission and frequency of follow-up differed between both cohorts, although it does not appear very likely that this will have had a major impact on the results. In the DAS-driven cohort, remission required a sustained DAS<1.6 at 3-monthly intervals, and as soon as the DAS rose >1.6, medication was restarted. In 15% of patients in remission based on a DAS <1.6, residual joint swelling (based on a 66/68 joint count) was still present. In the non-DAS-driven cohort, remission was based on the rheumatologist's opinion, including the absence of swollen joints at yearly evaluations. Restart of therapy and duration or frequency of follow-up were not protocolized.
It is difficult to speculate what the results might have been like if the cohorts had been more similar. Considering that the DAS-driven cohort had more disease activity at baseline and perhaps a more stringent definition of remission, one could argue that DAS-driven therapy leads to more sustained drug-free remission than is reflected by the current study. On the other hand, the earlier inclusion period and relative lack of combination therapy [21] . Part of the patients in the non-DAS-driven cohort who were included at an earlier point in time were not promptly treated with DMARDs, and a delay of DMARD therapy is associated with worse disease outcome [1, 5] . Initial combination therapy, used in a subpopulation of the DAS-driven cohort is associated with early and better suppression of disease activity, but was seldom prescribed in the non-DAS-driven cohort. It is remarkable in this respect that neither the specific treatment arm in the DAS-driven cohort (the BeSt study), nor the inclusion period and corresponding treatment strategy in the non-DAS-driven cohort (the EAC) were associated with sustained drug-free remission, confirming previous reports [14, 19] . This suggests that the effect of the differences in inclusion period and associated medication use on our results may have been limited. It is difficult to separate the effect of using more (novel) DMARDs from the effect of the DAS-driven strategy, as a tight control strategy with frequent DAS measurements inherently leads to rapid changes in medication. However, in our sensitivity analysis, we partly disentangled these effects by excluding all the patients with initial combination therapy, as well as the patients included before 1999, which did not result in a change in the observed remission rates.
With, or despite, the differences between the two cohorts, the rate of sustained drug-free remission did not differ between the the DAS-driven and non-DASdriven cohort. ACPA-negative patients achieved sustained drug-free remission more easily than ACPApositive patients, whether DAS-driven or not, but ACPA-positive patients, despite having a poorer prognosis in general [22] , had a slightly higher chance for achieving drug-free remission in the DAS-driven cohort than in the non-DAS-driven cohort. The more advanced analysis methods (employing propensity scores and interaction terms) yielded results compatible with the straightforward comparison of the prevalence of sustained drug-free remission: more remission in ACPA-positive patients after treatment with DAS-driven therapy (borderline significance). This argues in favour of the robustness of the analysis. We tentatively propose that this may indicate that with DAS-driven therapy sustained drug-free remission can be achieved more readily, even in patients with more unfavourable prognostic characteristics.
The absolute number of patients with sustained drug-free remission in both our cohorts is still low, and an important question is if and how we can attain more sustained drug-free remission in the future. Is sustained drug-free remission intrinsically possible only for certain patients, or should we be able to induce it in all patients? The similar rates of sustained drug-free remission in both cohorts as well as the higher sustained drug-free remission rate among ACPA-negative patients support the first statement, but the fact that with DAS-driven treatment drug-free remission was also attainable in more poor prognosis ACPA-positive patients supports the latter hypothesis. In addition, the finding of short symptom duration as a predictor of sustained drug-free remission may indicate a window of opportunity. The studied DAS-driven cohort aimed at a DAS-44 4 2.4, a cut-off that allows for some residual inflammation. Thus, actively aiming at even lower levels of disease activity, as well as starting treatment earlier and including the use of drug combinations and biologicals might result in more patients achieving early and sustained drug-free remission in patients with RA.
In summary, in a comparison of a DAS-driven and a non-DAS-driven therapy cohort, the occurrence and predictors of sustained drug-free remission appeared similar, but the DAS-driven cohort had more patients with an unfavourable prognosis. The fact that the presence of ACPA at presentation is associated with a significantly lower chance of achieving remission calls attention once more to the severe disease course associated with ACPA-positive RA. The results of this study suggest that ACPA-positive patients may especially benefit from tight disease control strategies. Future trials will hopefully shed more light on the optimal treatment strategy for this group of patients with their inherently poor prognosis.
Rheumatology key messages
. The absolute number of patients achieving drug-free remission in RA is limited. . Predictors of remission in RA are the absence of ACPA and a short symptom duration. . ACPA-positive RA patients more frequently achieved drug-free remission after DAS-driven therapy.
